Biotechnology company Nutra Pharma Corp. announced today that it has selected Alampharm to serve as the exclusive distributor in Lebanon for its Nyloxin-branded pain relievers.
“We are excited to be working with Alampharm to introduce our Nyloxin products into Lebanon,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As the leading pharmaceutical distributor in Lebanon, Alampharm is the perfect partner to introduce and distribute our products into the Middle East,” he continued.
Alampharm, with a strong presence in the Middle East, is a leading pharmaceutical company that operates in Lebanon. The company maintains high quality customer service by ensuring the safety of the product; they are focused and dedicated towards their customers, who in turn benefit from emerging new healthcare products such as Nyloxin. Alampharm, located in Beirut, also has medical representatives all over the country in addition to Syria and has been widely serving the pharmaceutical needs of medical institutes, hospitals, clinics, specialized medical facilities, pharmacies, as well as distributing domestically and regionally with great success since 2004.
Nyloxin is an over-the-counter pain reliever clinically proven to treat moderate to severe chronic pain. Nyloxin is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.
“We are so enthusiastic about continuing the registration of Nyloxin and introducing it to the market,” commented Dr. Khaled Alam, the Chief Executive Officer of Alampharm. “Nyloxin will be promoted through professional medical representatives to Orthopedics, Neurologists, and Oncologists and we will position Nyloxin as the first choice treatment of chronic pain management,” he continued. “In other words, the concept of analgesics in Lebanon and Syria will be changed and Nyloxin will constitute a revolution in the concept of pain treatment. The Arab Community is now ready to bring a positive change in their life, and put an end to their highly rated chronic aches. This will be procured by Nyloxin,” he concluded.
Previously, Nutra Pharma announced agreements with distributors in Mexico, Colombia and Venezuela. The drug registration process for both Cobroxin® and Nyloxin are currently being pursued in more than 20 countries.